Multimeric Biotherapeutics, Inc. is a privately held Delaware C corp that is based in San Diego. It leases laboratory space in the San Diego Science Center.
Multimeric has been financed by its founders, angel investors, and four NIH and CDC grants. The company now seeks either to out-license the FortiVac technology or to receive first-round funding to support the completion of IND-enabling studies for the FortiVac platorm.
Richard S. Kornbluth, MD, PhD
President & Chief Scientific Officer
Richard S. Kornbluth, MD, PhD is a founder of Multimeric. The company is based on the FortiVac technology that he invented in collaboration with Geoffrey W. Stone (who was formerly his postdoc at UCSD). Richard is both a basic scientist and a Board-Certified medical internist and pulmonary specialist. During an immunology postdoctoral fellowship at The Scripps Research Institute (TSRI), he filed his first patent on what is now known as CD40 ligand (CD40L). As an Associate Professor at UC San Diego (UCSD), he published more than 50 papers on the immunology and molecular virology of HIV, and wrote or co-wrote 26 funded grant applications. Dr. Kornbluth received a Bachelor’s degree from Harvard College, M.D. from New York Medical College, and Ph.D. in Pathology from Columbia University.
David A. Roth, PhD
Chief Operating Officer
David A. Roth, PhD is a founder of Multimeric who has extensive biotech management experience, including product and business development and research operations experience. He was most recently Senior Director – Research Operations at Halozyme Therapeutics, Inc. where he directed teams that generated several registered products. Prior to that, David was Senior Vice President for R&D at CODA Genomics (subsequently Verdezyne, Inc.). He is the author of 36 papers and 17 patents. Dr. Roth received his B.S., M.S., and Ph.D. degrees from the University of California at Berkeley, and took postdoctoral training at the UCSD School of Medicine.
Marc Herz, PhD
Marc Herz, PhD is a founder of Multimeric who has extensive experience in vaccine development. He was previously CEO of Pharmexa, Inc. (formerly Epimmune, Inc.), a publicly traded subsidiary of Pharmexa A/S that developed vaccines and cancer immunotherapies. At Pharmexa, he was responsible for 28 scientists and administrators and directed company strategy, business development, investor relations, and participated in multiple rounds of public fundraising. Marc received a Bachelor’s degree from Bowdoin College and a Ph.D. in Immunology from the University of Colorado Health Sciences Center and the National Jewish Medical and Research Center. He is currently a co-founder of GRI Bio, Inc., which is a biotech company focused on inflammatory, fibrotic and autoimmune diseases.
Beverly Dunlap, MSBA
Chief Financial Officer
Beverly Dunlap, MSBA joined Multimeric Biotherapeutics in 2017. She was previously Director of Business Development at Histogen, Inc. Prior to that, she was Program Manager at the College of Business Administration of San Diego State University. She has an undergraduate degree from Northern Illinois University, a Master’s degree in management from American University, and an MSBA from San Diego State University.